The best indicator for Bristol Myers Squibb (BMY)
We backtested 382 indicators across daily, weekly and hourly charts on real Bristol Myers Squibb (BMY) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Where Bristol Myers Squibb (BMY) stands
Computed from our own daily OHLCV history, not quoted from a third party. Moving averages use closing prices; "52-week" is the last 252 trading sessions.
QQE
On the weekly chart, this is the strongest risk-adjusted edge we found for Bristol Myers Squibb (BMY) over ~54.2 years — beating buy-and-hold by 0.8% CAGR.
Bristol Myers Squibb (BMY) on the weekly chart
The timeframe our backtest found best for this asset. The chart is live market data; the results above are hypothetical and historical.
Chart by TradingView. Loading it contacts tradingview.com, which may set its own cookies — see our privacy policy.
Best multi-indicator combo
Going long only when all 2 agree was the strongest confluence setup we found for Bristol Myers Squibb (BMY) — trailing buy-and-hold by 4.0% CAGR, out-of-sample. Fewer, higher-conviction trades than any single indicator.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | QQE ✓ | Weekly | 11.0% | 0.55 | -56.3% | 47.9% | 163 | 0.8% |
| 2 | Volume Flow Indicator ✓ | Weekly | 9.6% | 0.55 | -51.3% | 46.7% | 15 | -0.6% |
| 3 | DEMA 200 Trend ✓ | Weekly | 8.1% | 0.55 | -42.5% | 48.9% | 47 | -2.1% |
| 4 | Trendlines with Breaks ✓ | Weekly | 9.1% | 0.55 | -51.1% | 54.5% | 22 | -1.2% |
| 5 | SMC: Change of Character ✓ | Weekly | 9.4% | 0.54 | -51.6% | 57.1% | 21 | -0.9% |
| 6 | Ichimoku Cloud ✓ | Weekly | 8.3% | 0.53 | -56.1% | 39.7% | 58 | -2.0% |
| 7 | Positive Volume Index ✓ | Weekly | 7.8% | 0.53 | -53.8% | 38.1% | 21 | -2.4% |
| 8 | EMA 10/40 Cross ✓ | Weekly | 8.8% | 0.53 | -57.6% | 41.9% | 31 | -1.5% |
| 9 | WMA 100 Trend ✓ | Weekly | 8.2% | 0.52 | -67.5% | 39.2% | 51 | -2.0% |
| 10 | TRIX (21) ✓ | Weekly | 8.5% | 0.52 | -59.1% | 52.9% | 17 | -1.8% |
| 11 | G-Channel ✓ | Weekly | 8.4% | 0.52 | -59.0% | 44.1% | 59 | -1.8% |
| 12 | EMA 50/200 Cross ✓ | Daily | 8.6% | 0.51 | -62.0% | 36.7% | 30 | -1.8% |
| 13 | McGinley 200 Trend ✓ | Daily | 10.3% | 0.51 | -70.6% | 21.1% | 19 | -0.1% |
| 14 | EMA 20/50 Cross ✓ | Weekly | 8.2% | 0.51 | -62.5% | 47.6% | 21 | -2.1% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
What it would take to beat buy & hold on Bristol Myers Squibb (BMY)
3 of 721 tested setups beat buy-and-hold on Bristol Myers Squibb (BMY) outright. Another 249 could get there with leverage they would survive — but 342 would be liquidated by their own drawdown before they caught it.
| Indicator | Beats B&H unlevered | Leverage needed | Leverage survived |
|---|---|---|---|
| QQE | 1 | 1.24× | 2.07× |
| G-Channel | 1 | 1.5× | 4.0× |
| SMA 100 Trend | 1 | none needed | 3.0× |
| Chande Kroll Stop | — | 1.16× | 2.9× |
| Williams %R (28) | — | 1.25× | 3.68× |
| RSI (50) | — | 1.4× | 3.07× |
Out-of-sample, costs included. A setup is only listed if the leverage it needs is less than the leverage its own worst drawdown survives — when it isn't, no amount of leverage gets there. Volatility drag isn't modelled, so these are the optimistic case. Every indicator, ranked this way
For Bristol Myers Squibb (BMY), QQE on the weekly timeframe gave the best balance of return and risk in our test. It beat buy-and-hold — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get alerted when Bristol Myers Squibb’s signal flips
We track Bristol Myers Squibb daily. Its backtested best indicator, QQE (Weekly), is long right now — we'll email you the moment that changes. Free, no spam, unsubscribe any time.